Quantcast
Last updated on April 18, 2014 at 10:25 EDT

Latest hepatitis C Stories

2013-12-09 08:28:22

Developers of New Agents Must Show Superiority Over Marketed Therapies and Expect Tough Pricing and Reimbursement Negotiations, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) anticipate prescribing Gilead's...

FDA Approves Sovaldi For Treatment Of Chronic Hepatitis C
2013-12-08 07:27:34

redOrbit Staff & Wire Reports – Your Universe Online Sovaldi (sofosbuvir), a new drug that can treat hepatitis C infections, has been approved for sale by the US Food and Drug Administration (FDA), agency officials confirmed on Friday. According to Kim Painter of USA Today, the medication is manufactured by Gilead Sciences and “can be paired with other drugs to make treatment of the liver-damaging disease faster, easier and more effective.” Dr. Edward Cox, director of the...

2013-12-04 23:02:58

Reportbuyer.com just published a new market research report: Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022. London (PRWEB) December 04, 2013 Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no...

Hepatitis C Vaccine Efforts Bring Vaccine Closer To Reality
2013-11-30 05:22:41

redOrbit Staff & Wire Reports - Your Universe Online A hepatitis C vaccine is one step closer thanks to the efforts of scientists at The Scripps Research Institute (TSRI), who have managed to discover unexpected structural features of a protein used by the virus to infect liver cells. The study authors, whose work appears in Friday’s edition of the journal Science, state any successful hepatitis C vaccine would most likely target this protein, which is known as E2 envelope...

2013-11-26 23:32:05

AllMed webinar provides in-depth review of the latest in the standard of care for the treatment of hepatitis C virus (HCV) infection. Portland, OR (PRWEB) November 26, 2013 As the treatment of HCV continues to evolve, new and increasingly complex protocols present additional challenges in providing optimal care while meeting the unique needs of individual patients with HCV. During a recent webinar hosted by AllMed Healthcare Management, Dr. Anca Pop, board-certified gastroenterologist and...

2013-11-25 04:21:07

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 25, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-11-25 00:20:43

Action may speed generic manufacture, helping millions access affordable treatment NEW YORK, Nov. 25, 2013 /PRNewswire-USNewswire/ -- The Open Society Foundations today welcomed a challenge in India to Gilead Science's patent application for their new medicine, sofosbuvir, by the Initiative for Medicines, Access & Knowledge. The challenge, filed last week at the Kolkata Patent Office, would prevent Gilead from holding the monopoly on sofosbuvir's production and pricing. This...

2013-11-22 20:22:56

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 22, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-11-21 08:28:22

Surveyed Physicians Expect Nearly 20 Percent of Their Actively Treated HCV Patients to Be On a Newly Approved Regimen, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 21, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, following the launches of Gilead's sofosbuvir and Janssen/Medivir's simeprevir in the United States, currently marketed triple (Vertex's...

2013-11-18 08:28:30

- Confirms results of phase II studies, with consistent virologic response and tolerability profile NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved...


Latest hepatitis C Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »